2011 american society of clinical oncology.

Expanding our therapeutic options: Beta blockers for breast cancer?

Prostate cancer: evolution or revolution?

In this issue of Journal of Clinical Oncology, we present a special series on prostate cancer that illustrates how our understanding of the biology and therapy of this disease has changed over the last few years. This series comes on the heels of the 2011 Genitourinary Cancers Symposium (held February 17 to 19, 2011, in Orlando, FL), jointly sponsored by the American Society of Clinical Oncolog...

Future of treatment for low-risk prostate cancer: for all, for some, or for none?

ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Employment or Leadership Position: None Consultant or Advisory Role: Alberto F. Sobrero, Bayer (C), Amgen (C), Roche (C), Merck Serono (C), Astra Zeneca (C), sanofi-aventis (C) Stock Ownership: None Honoraria: Alber...

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.

ASCO-CAP guidelines for breast predictive factor testing: an update.

This brief report compares and contrasts the American Society of Clinical Oncology/College of American Pathologists guidelines for breast cancer predictive factor testing including the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor, type 2, erbB2 Guideline published in 2007 and the recently published Guideline for Estrogen Receptor ...

Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative.

CRA2500 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.